Tuberculosis, lung infections, and interstitial lung disease in AJRCCM 2000

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 10 I, 2001, Pages 1774-1788

  Tobin, Martin J ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; COLCHICINE; COLISTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROMYCIN; FIBRONECTIN; FLUOROURACIL; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ISONIAZID; KERATINOCYTE GROWTH FACTOR; PREDNISONE; PROGESTERONE; PROSTACYCLIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TAMOXIFEN; TOBRAMYCIN; UNINDEXED DRUG;

ALLERGIC PNEUMONITIS; BRONCHIECTASIS; BRONCHIOLITIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; HISTIOCYTOSIS X; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS PROTEINOSIS; LUNG CANCER; LUNG FIBROSIS; LUNG INFECTION; LUNG TOXICITY; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; OCCUPATIONAL LUNG DISEASE; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SARCOIDOSIS; SCLEROSIS; SIDE EFFECT; TUBERCULOSIS; WEGENER GRANULOMATOSIS;

EID: 0035891574     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.10.2108127     Document Type: Review

References (112)

1. Analysis of HLA antigens in Mycobacterium avium-intracellulare pulmonary infection
2. Familial pulmonary Mycobacterium avium complex disease
3. Specific HLA in pulmonary MAC infection in a Japanese population
4. Nitric oxide modulates interleukin-1β and tumor necrosis factor-α synthesis by alveolar macrophages in pulmonary tuberculosis
5. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis
6. Type 1 cytokines and the pathogenesis of tuberculosis
7. Mycobacterial lipoarabinomannan induces an inflammatory response in the mouse lung. A role for interleukin-1
8. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis
9. Tuberculosis in the homeless. A prospective study
10. Risk of tuberculosis infection and tuberculous meningitis after discontinuation of bacillus Calmette-Guérin in Beijing
11. Comparison testing of current (PPD-S1) and proposed (PPD-S2) reference tuberculin standards
12. Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease
13. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations
14. Tuberculosis elimination: Are we willing to pay the price?
15. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis
16. Outcomes of contact investigations of infectious tuberculosis patients
17. Targeting tuberculosis prevention
18. Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: Reappraising the estimates of risk
19. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: An outcome and cost-effectiveness analysis
20. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines
21. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy
22. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens
23. Targeted tuberculin testing and treatment of latent tuberculosis infection (official statement of the American Thoracic Society; adopted by the ATS Board of Directors, July 1999; endorsed by the Council of the Infectious Diseases Society of America (IDSA))
24. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection?
25. A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis
26. Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis
27. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: Experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil
28. Sensitive identification of mycobacterial species using PCR-RFLP on bronchial washings
29. Diagnosis of tuberculosis by a visually detectable immunoassay for lipoarabinomannan
30. Diagnostic standards and classification of tuberculosis in adults and children (official statement of the American Thoracic Society and the Centers for Disease Control and Prevention; adopted by the ATS Board of Directors, July 1999; endorsed by the Council of the Infectious Disease Society of America, September 1999)
31. Predicting the outcome of therapy for pulmonary tuberculosis
32. Increased cortisol:cortisone ratio in acute pulmonary tuberculosis
33. Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes
34. In vitro ethanol suppresses alveolar macrophage TNF-α during simian immunodeficiency virus infection
35. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity
36. + T cells in the lungs of patients with HIV infection and T-cell alveolitis
37. A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era
38. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons
39. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection
40. Pneumocystis carinii and geographic clustering: Evidence for transmission of infection
41. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco
42. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: Validation of severity criteria
43. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension
44. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection
45. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia
46. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy
47. Influenza virus inhibits Iysozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis
48. Accumulation of macrophages with dendritic cell characteristics in the pulmonary response to Listeria
49. Neutrophil-mediated degradation of lung proteoglycans: Stimulation by tumor necrosis factor-α in sputum of patients with bronchiectasis
50. The utility of open lung biopsy in patients with hematologic malignancies
51. Utility of the antibody response to a conjugated Haemophilus influenzae type B vaccine for diagnosis of primary humoral immunodeficiency
52. Bacteriology of infected cavitating lung tumor
53. Varicella-zoster virus detection by polymerase chain reaction using bronchoalveolar lavage specimens
54. Differential patterns of apoptosis in resolving and nonresolving bacterial pneumonia
55. Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications
56. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin
57. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis
58. Reduced nasal nitric oxide in diffuse panbronchiolitis
59. Severe bronchiectasis in patients with "cystlike" structures within the ciliary shafts
60. An investigation into causative factors in patients with bronchiectasis
61. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms
62. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
63. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia
64. Fibroblast contractility: Usual interstitial pneumonia and nonspecific interstitial pneumonia
65. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia
66. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival
67. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study
68. Does idiopathic pulmonary fibrosis increase lung cancer risk?
69. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis
70. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent
71. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias
72. Manganese superoxide dismutase and catalase are coordinately expressed in the alveolar region in chronic interstitial pneumonias and granulomatous diseases of the lung
73. Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis
74. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor
75. Induction of lung fibroblast apoptosis by soluble fibronectin peptides
76. Cyclophosphamide prevents systemic keratinocyte growth factor-induced up-regulation of surfactant protein A after allogeneic transplant in mice
77. Idiopathic pulmonary fibrosis: Diagnosis and treatment (international consensus statement of the American Thoracic Society, and the European Respiratory Society)
78. Pulmonary immunobiology and inflammation in pulmonary diseases
79. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis
80. Lung T-helper cells expressing T-cell receptor AV2S3 associate with clinical features of pulmonary sarcoidosis
81. Familial sarcoidosis is linked to the major histocompatibility complex region
82. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis
83. CD13/aminopeptidase N,a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis
84. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis
85. Is high-resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis?
86. Severe pulmonary hypertension in histiocytosis X
87. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study
88. Pulmonary lymphangioleiomyomatosis in a man
89. Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome
90. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's granulomatosis
91. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients
92. Serological diagnosis of idiopathic pulmonary alveolar proteinosis
93. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis
94. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis
95. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support
96. Pulmonary glutathione levels in acute episodes of farmer's lung
97. Inhibition of binding of E- and P-selectin to sialyl-Lewis X molecule suppresses the inflammatory response in hypersensitivity pneumonitis in mice
98. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis
99. Cryptococcus albidus-induced summer-type hypersensitivity pneumonitis
100. Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects
101. Alterations in large and small proteoglycans in bleomycin-induced pulmonary fibrosis in rats
102. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury
103. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice
104. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice
105. Antisense oligonucleotides to NF-κB improve survival in bleomycin-induced pneumopathy of the mouse
106. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice
107. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis
108. Pneumoconiosis-related lung cancers: Preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis
109. Changes in bronchoalveolar Iavage indices associated with radiographic classification in coal miners
110. Chest pain in asbestos-exposed individuals with benign pleural and parenchymal disease
111. Vitronectin protects alveolar macrophages from silica toxicity
112. Mast cell basic fibroblast growth factor in silicosis